Targeted Therapy for HER2 and HER3-Positive Breast Cancer: Navigating the Evolving Treatment Landscape

Targeted Therapy for HER2 and HER3-Positive Breast Cancer: Navigating the Evolving Treatment Landscape is organized by CME Outfitters, LLC.

Premiere Date: Wednesday, September 16, 2020
Credit Expiration Date: Thursday, September 16, 2021

This activity offers CE credit for:
• Pharmacists (ACPE)
• Nurses (CNE)
• Pharmacists (ACPE)
• ABIM (MOC)
• Other

Target Audience:
Hematologists/oncologists, OB/GYNs, surgeons, pathologists, PAs, NPs, nurses, and pharmacists

How many CME credits can be earned by attending Targeted Therapy for HER2 and HER3-Positive Breast Cancer: Navigating the Evolving Treatment Landscape CME Conference?

Credit Information:
CME Credit (Physicians):
CME Outfitters, LLC, assigns this enduring online CME activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CNE Credit (Nurses):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.5 contact hours.

CPE Credit (Pharmacists):
ACPECME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.5 contact hours (0.15 CEUs).

ABIM/MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.

Note to PAs:
PAs may claim a maximum of 1.5 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.

Statement of Need:
Breast cancer (BC) is a heterogeneous disease with human epidermal growth factor receptor 2 (HER2) overexpression and/or amplification observed in 20%-30% of cases. HER2-positive (+) BC correlates with poor clinical outcomes unless appropriately treated with targeted therapy. Despite significant therapeutic advances, many patients experience disease progression with resistance to targeted agents developing over the course of treatment.

This CME Outfitters Live and OnDemand webcast will provide up-to-date education on this rapidly evolving field, in order to better tailor treatment strategies, leading to improved patient outcomes. Additionally, the faculty will discuss COVID-19 and its impact on patients with BC.

What are the objectives of Targeted Therapy for HER2 and HER3-Positive Breast Cancer: Navigating the Evolving Treatment Landscape CME Conference?

Learning Objectives:
At the end of this CE activity, participants should be able to:
• Apply HER2 testing guidelines for improved treatment selection in breast cancer.
• Evaluate clinical trial data for novel and emerging therapies for the management of patients with low HER2 expression, resistant to HER2-directed therapies, and HER3+ BC.
• Expand the use of telemedicine in BC care.

The following learning objectives pertain only to those requesting CNE or CPE credit:
• Summarize HER2 testing guidelines for improved treatment selection in BC.
• Evaluate clinical trial data for novel and emerging therapies for the management of patients with low HER2 expression, resistant to HER2-directed therapies, and HER3+ BC.
• Describe ways to expand the use of telemedicine in BC care.